MRK
Merck & Co, INC
NYSE
8-K: Merck Reports Mixed Q4 and Full-Year 2023 Results Amidst Restructuring and Strategic Investments
Sentiment:
Quarterly Report
1 February 2024 6:39 AM
Merck's fourth-quarter and full-year 2023 results show sales growth driven by oncology and vaccines, but are impacted by a significant charge related to a collaboration with Daiichi Sankyo and restructuring costs.
Worse than expected
The company reported a GAAP loss per share for the fourth quarter and a significantly lower EPS for the full year compared to the previous year, primarily due to charges related to collaborations and business development transactions.
Non-GAAP EPS also declined significantly compared to the previous year, indicating a weaker financial performance despite excluding certain items.
Summary
- Merck's fourth-quarter worldwide sales reached $14.6 billion, a 6% increase compared to the same period in 2022, or 13% excluding the impact of LAGEVRIO and foreign exchange.
- Full-year worldwide sales were $60.1 billion, a 1% increase from 2022, or 12% excluding LAGEVRIO and foreign exchange.
- Key growth drivers included KEYTRUDA, with sales up 19% to $25.0 billion for the year, and GARDASIL/GARDASIL 9, with sales up 29% to $8.9 billion.
- LAGEVRIO sales declined significantly by 75% to $1.4 billion for the full year.
- The company reported a GAAP loss per share of $0.48 for the fourth quarter and $0.14 for the full year, impacted by a $1.69 per share charge for a collaboration with Daiichi Sankyo and $6.21 per share for certain business development transactions.
- Non-GAAP EPS was $0.03 for the fourth quarter and $1.51 for the full year.
- Merck approved a new restructuring program expected to cost approximately $4.0 billion pretax, with 60% being non-cash charges.
- The company anticipates full-year 2024 sales to be between $62.7 billion and $64.2 billion and non-GAAP EPS to be between $8.44 and $8.59.
Sentiment
Score: 5
Explanation: The sentiment is neutral to slightly negative. While there is strong growth in key areas like oncology and vaccines, the significant charges, restructuring costs, and decline in LAGEVRIO sales temper the positive aspects. The forward-looking guidance is positive, but the current results are mixed.
Positives
- Strong growth in oncology, particularly with KEYTRUDA, and vaccines, especially GARDASIL/GARDASIL 9.
- Excluding LAGEVRIO and foreign exchange, sales growth was robust.
- The company is actively advancing its pipeline with multiple Phase 3 trial initiations.
- FDA Priority Review was granted for key pipeline candidates.
- The company is making strategic acquisitions and collaborations to augment its pipeline.
- The company reached more than 500 million people with its medicines last year alone, over half of which were donations.
Negatives
- Significant decline in LAGEVRIO sales impacted overall revenue growth.
- GAAP earnings were significantly impacted by charges related to collaborations and business development transactions.
- The new restructuring program will incur substantial costs.
- The company experienced a GAAP loss per share for the fourth quarter and a low EPS for the full year.
- The effective tax rate was high for both the fourth quarter and full year due to charges for asset acquisitions and the Daiichi Sankyo collaboration.
Risks
- The restructuring program may present operational challenges and incur higher than expected costs.
- Dependence on the success of pipeline candidates and their regulatory approvals.
- The company is exposed to currency exchange rate fluctuations, particularly with the devaluation of the Argentine peso.
- The company is exposed to litigation, including patent litigation, and/or regulatory actions.
- The company is exposed to general industry conditions and competition.
Future Outlook
Merck anticipates full-year 2024 sales to be between $62.7 billion and $64.2 billion, with non-GAAP EPS between $8.44 and $8.59. The outlook includes the impact of the Harpoon Therapeutics acquisition and a negative impact from foreign exchange.
Management Comments
- Robert M. Davis, chairman and chief executive officer, stated that 2023 was a very strong year for Merck.
- He expressed pleasure in the progress made to develop and deliver transformative therapies and vaccines.
- He highlighted the company's reach of over 500 million people with medicines, including donations.
- He mentioned investments of approximately $30 billion in research and development.
- He expressed confidence that the company's strong momentum will continue.
Industry Context
The results reflect the ongoing trends in the pharmaceutical industry, with strong growth in oncology and vaccines, while also highlighting the challenges of managing product lifecycles, as seen with the decline in LAGEVRIO sales. The restructuring program indicates a strategic shift towards new modalities and efficiency improvements, which is a common theme in the industry.
Comparison to Industry Standards
- Merck's KEYTRUDA sales growth of 19% is comparable to other leading oncology drugs, such as Bristol Myers Squibb's Opdivo, which has also seen strong growth in recent years, although specific growth rates vary.
- The 29% growth in GARDASIL/GARDASIL 9 sales is a strong performance in the vaccine market, where companies like Pfizer and GSK also compete with their own vaccine portfolios.
- The decline in LAGEVRIO sales is similar to what other companies have experienced with COVID-19 treatments as the pandemic has waned, such as Pfizer's Paxlovid.
- The restructuring program is similar to actions taken by other large pharmaceutical companies to optimize their manufacturing networks and reduce costs, such as Novartis and Sanofi.
- Merck's R&D spending of $30 billion is a significant investment, comparable to other large pharmaceutical companies like Roche and Johnson & Johnson, who also invest heavily in research and development.
Stakeholder Impact
- Shareholders will be impacted by the lower earnings and restructuring costs, but may benefit from future growth and pipeline advancements.
- Employees may be affected by the restructuring program, with potential job losses or changes in roles.
- Customers will benefit from the continued development of new and innovative therapies and vaccines.
- Suppliers may be impacted by changes in the company's manufacturing network.
- Creditors will be impacted by the company's financial performance and restructuring activities.
Next Steps
- The company will continue to execute its restructuring program.
- Merck will focus on advancing its pipeline candidates through clinical trials and regulatory approvals.
- The company will integrate the recently acquired Harpoon Therapeutics.
- Merck will continue to monitor and manage the impact of foreign exchange rates.
- The company will provide updates on its progress in future financial reports.
Legal Proceedings
- The company incurred a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
Key Dates
- January 29, 2024: Date the company approved the 2024 Restructuring Program.
- February 1, 2024: Date of the earnings press release and 8-K filing.
- June 17, 2024: FDA PDUFA date for V116.
- June 26, 2024: FDA PDUFA date for patritumab deruxtecan.
Keywords
Merck, MRK, Pharmaceuticals, Oncology, Vaccines, KEYTRUDA, GARDASIL, LAGEVRIO, Restructuring, Financial Results, Earnings, Pipeline, FDA, Non-GAAP, EPS
MRK
Merck & Co, INC
NYSE
Sector: TBD
Filings with Classifications
Delay expected
2 May 2025 4:10 PM
Quarterly Report
- The company has experienced manufacturing delays related to ProQuad and Varivax, and anticipates that some international markets will experience supply constraints during 2025.
Worse than expected
2 May 2025 4:10 PM
Quarterly Report
- Worldwide sales were down 2% year over year.
- Gardasil/Gardasil 9 sales declined significantly by 41% due to lower demand in China.
- Lagevrio sales decreased by 71% due to lower demand in the Asia Pacific region.
Worse than expected
24 April 2025 6:45 AM
Quarterly Report
- Total worldwide sales decreased by 2% compared to the first quarter of 2024.
- The full-year 2025 non-GAAP EPS outlook was revised to reflect a negative impact from an anticipated one-time charge of approximately $0.06 per share related to the license agreement with Hengrui Pharma.
Worse than expected
25 February 2025 4:19 PM
Annual Results
- The company expects a significant decline in Gardasil/Gardasil 9 sales in China for 2025.
- The company expects U.S. sales of Keytruda to decline beginning in January 2028 due to government pricing under the IRA.
Delay expected
25 February 2025 4:19 PM
Annual Results
- The company is currently experiencing manufacturing delays related to Varivax and ProQuad which will result in supply constraints in 2025.
Better than expected
4 February 2025 6:45 AM
Earnings Release
- The company's full year sales of $64.2 billion were better than the $60.115 billion in the prior year.
- The company's full year GAAP EPS of $6.74 was better than the $0.14 in the prior year.
- The company's full year Non-GAAP EPS of $7.65 was better than the $1.51 in the prior year.
Better than expected
29 January 2025 6:27 PM
SEC Form 4
- The performance shares were paid out at 169 percent of target awards, indicating that the company exceeded its performance goals during the three-year period.
Better than expected
29 January 2025 6:25 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating that the company exceeded its performance goals.
Better than expected
29 January 2025 6:23 PM
SEC Form 4
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:21 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:19 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:17 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:14 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:12 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Better than expected
29 January 2025 6:09 PM
SEC Form 4 Filing
- The performance shares were paid out at 169 percent of target awards, indicating better than expected performance.
Delay expected
6 November 2024 4:05 PM
Quarterly Report
- Merck is currently working to incorporate guidance from regulatory authorities into the company's clinical trial design for its two prospective Gardasil 9 single-dose trials, consequently, the trials will not be started in 2024.
Worse than expected
6 November 2024 4:05 PM
Quarterly Report
- Net income attributable to Merck decreased in Q3 2024 compared to Q3 2023 due to significant acquisition charges and restructuring costs.
Worse than expected
31 October 2024 6:44 AM
Quarterly Report
- The company's GAAP and non-GAAP EPS were lower than the previous year due to significant charges related to business development transactions.
Delay expected
5 August 2024 4:02 PM
Quarterly Report
- The company received a complete response letter from the FDA for patritumab deruxtecan due to manufacturing facility issues.
Better than expected
5 August 2024 4:02 PM
Quarterly Report
- The company's net income improved significantly compared to the same period last year, which had a net loss.
- The company's sales growth exceeded expectations, driven by strong performance in oncology and vaccines.
- The company's research and development expenses decreased due to lower charges for business development transactions.
Worse than expected
30 July 2024 6:41 AM
Quarterly Report
- The full-year non-GAAP EPS outlook was lowered due to a one-time charge of approximately $1.3 billion, or $0.51 per share, for the acquisition of EyeBio.
Capital raise
30 May 2024 4:14 PM
Debt Issuance Announcement
- MSD Netherlands Capital B.V. raised $3.4 billion through the issuance of senior notes.
- The proceeds from the offering will be used for general corporate purposes.
Better than expected
3 May 2024 4:10 PM
Quarterly Report
- The company's sales and net income exceeded expectations due to strong performance in oncology and vaccines.
- Keytruda sales growth was higher than anticipated, driven by new indications and continued uptake.
- The company's gross margin improved due to favorable product mix and lower royalty rates.
Better than expected
25 April 2024 6:41 AM
Quarterly Report
- Merck's first quarter sales and earnings exceeded expectations, driven by strong growth in key products.
- The company raised and narrowed its full-year outlook, indicating increased confidence in future performance.
Worse than expected
26 February 2024 4:06 PM
Annual Results
- The company experienced a significant decrease in net income from continuing operations, with GAAP net income at $365 million and non-GAAP net income at $3.837 billion, which is worse than the previous year.
- The company experienced a substantial decline in Lagevrio sales, which is worse than the previous year.
Worse than expected
1 February 2024 6:39 AM
Quarterly Report
- The company reported a GAAP loss per share for the fourth quarter and a significantly lower EPS for the full year compared to the previous year, primarily due to charges related to collaborations and business development transactions.
- Non-GAAP EPS also declined significantly compared to the previous year, indicating a weaker financial performance despite excluding certain items.
Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.